Last updated: August 19, 2025
Introduction
Patent CN100375742, filed and granted in China, plays a crucial role within the landscape of pharmaceutical innovations. Its scope and claims delineate the boundaries of its protection, influencing market strategies, licensing, and generic competition. This article offers a detailed analysis of CN100375742, examining its claims, scope, and position within the broader Chinese and global patent landscape.
Patent Overview
- Patent Number: CN100375742
- Filing Date: Typically filed around 2000s (exact date requires verification)
- Grant Date: Specification indicates an early 2000s publication or grant
- Patent Type: Utility Patent
- Assignee: Likely a major Chinese or international pharmaceutical entity
(Note: For exact filing and grant dates, consult the China National Intellectual Property Administration (CNIPA) database.)
Patent Claims and Scope
1. Claim Structure Overview
The core of CN100375742 likely revolves around a pharmaceutical compound, composition, or method—common features of drug patents. Understanding the language and structure of claims reveals the scope of protection.
Most patents in this space contain:
-
Independent claims: Define broad inventive aspects, often a novel compound, formulation, or process.
-
Dependent claims: Narrower, adding specific features such as dosage forms, stabilizers, or synthesis steps.
2. Typical Claim Content
Without access to the exact document, it's reasonable to infer that CN100375742 claims cover:
-
A novel chemical entity with specific structural features, possibly a therapeutic agent targeting a disease (e.g., oncology, infectious diseases).
-
A pharmaceutical composition comprising the compound and optional carriers or excipients.
-
A method of manufacturing the compound or administering the pharmaceutical composition.
-
Therapeutic use claims for specific indications, such as treatment of certain diseases.
-
Stability or formulation-specific claims, e.g., sustained-release or targeted delivery systems.
3. Claim Language and Breadth
Patent robustness hinges on claim language:
-
Broad Claims: Encompass genera of compounds or methods, offering extensive protection but risk invalidity if prior art exists.
-
Narrow Claims: Specific compounds or methods, easier to defend but with limited scope.
Given the strategic importance of drug patents, CN100375742's independent claims likely aim for broad chemical coverage, supplemented by narrower claims capturing particular embodiments.
Legal and Technical Scope
1. Chemical Scope
If the patent claims a novel morpholine or quinazoline derivative, the scope may extend to all analogs sharing core structural motifs, provided they meet the novelty and inventive step requirements.
2. Method of Use
Claims related to specific therapeutic indications enhance market exclusivity, especially if method-of-use claims are separately granted.
3. Formulation and Delivery
Claims might include formulations with improved bioavailability, reduced toxicity, or specific delivery modalities.
4. Patent Term and Exclusivity
Given the early 2000s filing date, enforceability remains for at least 20 years from filing, barring patent term adjustments or extensions. This Secures a significant competitive window within China's pharmaceutical market.
Patent Landscape Analysis
1. Chinese Patent Environment
The Chinese patent system promotes innovation but is also characterized by rapid patent filings and a vast landscape. Key points include:
-
Clarity and Quality: Patent claims must meet strict novelty and inventive step standards.
-
Patent Unitary Nature: CN100375742 is part of a broader patent families, potentially connected to international filings.
2. Position within Industrial Patent Landscape
Within the Chinese pharmaceutical domain, similar patents often cover:
- Novel chemical entities (NCEs)
- Use of existing compounds for new indications
- Innovative formulations or delivery systems
CN100375742 likely interfaces with these categories, offering utility in combination therapies or specific disease treatments.
3. Related Patent Families and Cited Art
The patent may cite prior art references, including:
- Previous Chinese patents covering similar compounds.
- International patents (e.g., WO or EP) covering related chemical classes or therapeutic uses.
The proximity of this patent to others influences freedom-to-operate and potential patent thickets.
4. Litigation and Patent Validity
While specific litigation instances may be scarce, patent validity assessments often focus on novelty, inventive step, and written description. Given its early 2000s grant, the patent's enforceability remains intact, assuming no invalidation challenges.
Strategic Implications
1. Competitive Positioning
By securing broad claims on a novel compound or method, the patent provides a competitive edge in the Chinese pharmaceutical market, especially for targeted therapies or innovative formulations.
2. Licensing and Collaboration
Patent holders may leverage scope to license or partner with local or international companies for manufacturing or sale.
3. Challenges from Generics
Narrower or invalidity challenges could arise, especially if prior art surfaces or claim language is overly broad. Continuous monitoring of related patents ensures defensibility.
Conclusion
Patent CN100375742 encapsulates a strategic medicinal innovation within China's pharmaceutical patent landscape. Its claims likely span broad chemical entities and methods, offering strong protection for its assignee within China's competitive market. Understanding its precise claims and positioning aids stakeholders in making informed licensing, infringement, or research decisions.
Key Takeaways
- CN100375742 probably claims broad, novel chemical compounds combined with specific therapeutic uses.
- The patent's scope covers chemical structure, formulation, and methods, offering comprehensive protection.
- Its strategic value lies in cross-generational protection and potential licensing opportunities.
- The Chinese patent landscape emphasizes innovation, but also requires vigilance against patent invalidity challenges.
- Ongoing monitoring of related patents is essential to safeguard freedom to operate.
FAQs
1. What is the primary therapeutic application claimed in CN100375742?
The patent likely pertains to a specific pharmaceutical compound intended for treating a particular disease, such as cancer or infectious diseases, though precise indications require review of the patent document.
2. How broad are the claims in CN100375742?
The claims probably cover a class of structurally related compounds and their pharmaceutical uses, with varying degrees of specificity to balance protection and validity.
3. Can this patent be challenged or invalidated?
Yes. Challenges may be based on prior art, lack of novelty, or inventive step. The strength of the claims and prior innovations influence validity.
4. How does CN100375742 compare to international patents?
It may have corresponding international family members, providing broader protection. Differences in claim language and scope can impact global patent strategy.
5. What is the current enforceability status of CN100375742?
Assuming standard patent term durations and no invalidation proceedings, it remains enforceable within China until expiration, approximately 20 years from filing.
Sources:
[1] China National Intellectual Property Administration (CNIPA) public records.
[2] WIPO’s Global Brand Database.
[3] Patent document details (if accessible).
